New drug E7386 tested for tough cancers
NCT ID NCT03833700
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new drug called E7386 in about 70 people with advanced solid tumors, including colorectal cancer. The main goal is to check safety and find the right dose. Participants have tumors that no longer respond to standard treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADRENOCORTICAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Eisai Trial Site #1
Chuo Ku, Tokyo, Japan
-
Eisai Trial Site #2
Kashiwa, Chiba, Japan
-
Eisai Trial Site #3
Nagaizumi-cho, Shizuoka, Japan
-
Eisai Trial Site #4
Fukuoka, Japan
-
Eisai Trial Site #5
Sapporo, Hokkaido, Japan
-
Eisai Trial Site#6
Osaka, Japan
-
Eisai Trial Site#7
Nagoya, Aichi-ken, Japan
-
Eisai Trial Site#8
Sendai, Miyagi, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict who will survive a bowel surgery leak?
- Can a Two-Drug attack shrink Hard-to-Treat colorectal tumors?
- Can a new drug ST316 shrink Hard-to-Treat tumors?
- A mobile app aims to turn health awareness into action — a trial puts it to the test
- Can a walking routine alter cancer biomarkers? new trial investigates
- Web tool aims to empower rare cancer patients in genomic choices